Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,069 public trials 582 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT07455851

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

Mosaic Trial for Stem Cell Transplant Recipients

NCT06960993

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Bone Marrow Transplant, +22 more
Locations
  • Georgetown University School of Medicine Washington D.C., District of Columbia, United States
  • Northwestern University Feinberg School of Medicine Chicago, Illinois, United States
  • Hackensack Meridian Health Nutley, New Jersey, United States
View Trial Details
Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Scripps Clinic Torrey Pines La Jolla, California, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Indiana University Health Simon Cancer Center Indianapolis, Indiana, United States
  • Dana Farber/Harvard Cancer Center Boston, Massachusetts, United States
View all 42 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Southern California /ID# 272414 Los Angeles, California, United States
  • Yale University School of Medicine /ID# 272447 New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute /ID# 271846 Boston, Massachusetts, United States
  • University of Michigan Health System - Ann Arbor /ID# 271536 Ann Arbor, Michigan, United States
View all 48 locations
View Trial Details
Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Conditions
Blood Protein Disorders, Bronchial Diseases, Bronchiolitis, +43 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • University of California San Diego Medical Center La Jolla, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • St. Joseph Hospital Center for Cancer Prevention and Treatment Orange, California, United States
View all 175 locations
View Trial Details
Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Aalborg Sygehus Syd Aalborg, Denmark
  • Aarhus Universitetshospital Aarhus N, Denmark
  • Rigshospitalet Copenhagen, Denmark
  • Odense University Hospital Odense, Denmark
View all 68 locations
View Trial Details
Recruiting

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Sun yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Tianjin Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
  • The First Affiliated Hospital of Nanchang University Nanchang, China
  • The First Affiliated Hospital of Wenzhou Medical University Wenzhou, China
View Trial Details
Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Icahn School of Medicine at Mt. Sinai New York, United States
View all 38 locations
View Trial Details

Related conditions